Evidence map›Paper›PMID 29148977›Full record

ReviewBiological chemistry2018

The role of microRNAs in chronic respiratory disease: recent insights.

Lindsay R Stolzenburg, Ann Harris

Open access · bronzeAbstract readReview
In one paragraph

Review in Biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Review
  3. Participation of miRNA-23a-3p in Pulmonary Tuberculosis Through Macrophages via the JAK-STAT Pathway.International journal of chronic obstructive pulmonary disease · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. A miRNA-21-Mediated PTEN/Akt/NF-κB Axis Promotes Chronic Obstructive Pulmonary Disease Pathogenesis.International journal of chronic obstructive pulmonary disease · 2024
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Hsa-Mir-320c, Hsa-Mir-200c-3p, and Hsa-Mir-449c-5p as Potential Specific miRNA Biomarkers of COPD: A Pilot Study.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lindsay R StolzenburgHuman Molecular Genetics Program, Lurie Children's Research Center, Chicago, IL 60614, USA.
Ann HarrisHuman Molecular Genetics Program, Lurie Children's Research Center, Chicago, IL 60614, USA.
Northwestern University · US

Funding

Mining open chromatin to define molecular mechanisms of CF modifier genesR01HL117843 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI HARRIS, ANN, KNOWLES, MICHAEL R · 2013 to 2017
$2.9M
A novel microRNA in pulmonary fibrosisF31HL126458 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI STOLZENBURG, LINDSAY · 2015 to 2016
$72k
NHLBI NIH HHS F31 HL126458NHLBI NIH HHS R01 HL117843
6 · The paper itself

Abstract

Chronic respiratory diseases encompass a group of diverse conditions affecting the airways, which all impair lung function over time. They include cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and asthma, which together affect hundreds of millions of people worldwide. MicroRNAs (miRNAs), a class of small non-coding RNAs involved in post-transcriptional gene repression, are now recognized as major regulators in the development and progression of chronic lung disease. Alterations in miRNA abundance occur in lung tissue, inflammatory cells, and freely circulating in blood and are thought to function both as drivers and modifiers of disease. Their importance in lung pathology has prompted the development of miRNA-based therapies and biomarker tools. Here, we review the current literature on miRNA expression and function in chronic respiratory disease and highlight further research that is needed to propel miRNA treatments for lung disorders towards the clinic.

Indexed as

AnimalsAsthmaBiomarkersHumansIdiopathic Pulmonary FibrosisLungMicroRNAsPulmonary Disease, Chronic ObstructiveBiomarkersMicroRNAschronic diseaselungmicroRNArespiratory diseasetherapy

Identifiers

PMID29148977
PMCPMC8041099
OpenAlexW2769298830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.